AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

The healthcare sector is entering a transformative phase driven by breakthrough innovations in AI, obesity drugs, and diagnostics—areas that are creating entirely new multi-billion dollar markets with minimal macroeconomic sensitivity. Shivani Vora of Parnassus Growth Equity Fund argues that while investors are still underappreciating the long-term impact of these trends, the real value lies in first-mover companies that can leverage AI to accelerate drug discovery, dominate emerging markets like oral GLP-1 weight loss pills, and pioneer non-invasive diagnostics. She highlights Natera’s revolutionary work in cancer monitoring through blood-based DNA testing and the potential of multi-cancer early detection panels, which could unlock a $70–80 billion market. Despite recent sell-offs, she sees deep growth runway in medical technology, particularly Intuitive Surgical’s DaVinci 5 robotic platform, which benefits from entrenched hospital adoption, AI integration, and a global penetration rate still in the low teens. Vora emphasizes that healthcare’s unique resilience—where life-saving therapies remain in demand regardless of economic or political shifts—makes it a powerful portfolio counterbalance. The sector’s ability to generate new markets, combined with AI-driven efficiency gains in R&D and clinical trials, suggests that the full impact won’t be priced in for another three to five years.